Loading…
Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation
This study aimed to assess the efficacy of dual T-cell suppression using individually tailored doses of antithymocyte globulin (ATG) and attenuated dose of post-transplant cyclophosphamide (PTCy) in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). We conducted a retrospective ana...
Saved in:
| Published in: | Scientific reports 2024-06, Vol.14 (1), p.13885-9, Article 13885 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c492t-bae15839005af84c291f4314ab90e6ffc8c849ddad8df93e25387c2bc992362b3 |
| container_end_page | 9 |
| container_issue | 1 |
| container_start_page | 13885 |
| container_title | Scientific reports |
| container_volume | 14 |
| creator | Kim, Dong Hyun Shin, Dong-Yeop Koh, Youngil Kim, Inho Yoon, Sung-Soo Byun, Ja Min Hong, Junshik |
| description | This study aimed to assess the efficacy of dual T-cell suppression using individually tailored doses of antithymocyte globulin (ATG) and attenuated dose of post-transplant cyclophosphamide (PTCy) in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). We conducted a retrospective analysis of 78 adults with acute leukemia or myelodysplastic syndrome who underwent haplo-HSCT using intravenous busulfan and fludarabine conditioning. Thirty-two patients received attenuated ATG/PTCy, while 46 patients received ATG (7.5 mg/kg) as GVHD prophylaxis. The 100-day cumulative incidence of grade III-IV (9.7% vs. 32.4%,
P
= 0.018) acute GVHD, as well as 2-year moderate-severe chronic GVHD (13.9% vs. 43.9%,
P
= 0.018) in the ATG/PTCy group were significantly lower than those in the ATG group. The 2-year overall survival was comparable between the two groups. However, 2-year GVHD-free, relapse-free survival in the ATG/PTCy group was significantly higher compared to that in the ATG group (38.9% vs. 21.7%,
P
= 0.021). Moreover, during post-engraftment period, the ATG/PTCy group exhibited lower incidences of life-threatening bacterial (12.5% vs. 37%,
P
= 0.033) and viral infection (0% vs. 17.4%,
P
= 0.035) than the ATG group. In conclusion, the combination of individually tailored ATG and low-dose PTCy appears to be a promising strategy in haplo-HSCT. |
| doi_str_mv | 10.1038/s41598-024-64361-5 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9e6b3a6008c745668dcce82783a22d7a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9e6b3a6008c745668dcce82783a22d7a</doaj_id><sourcerecordid>3068630812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-bae15839005af84c291f4314ab90e6ffc8c849ddad8df93e25387c2bc992362b3</originalsourceid><addsrcrecordid>eNp9kstu1DAUhiMEolXpC7BAltiwCfiWjL1CqNwqVWJT1pZjOxOPnDjYTqt5Ml6PM5PSCwuyyZHPfz7_x_qr6jXB7wlm4kPmpJGixpTXLWctqZtn1SnFvKkpo_T5o_qkOs95h-FrqOREvqxOmBACC9acVr8_Lzqg69q4EJB1c3DFxwnd-jIgP1l_4y0Iwh4V7UNMziI9FV-XYT9Gsy8ObUPsluAnOIdeKW5adAGZjdmh2KM55lKXpKc8BxhFZm9CnIeY50GP3jq4BQ16DhFqIBtwM7vk58ElKHNxIzp6e0Dog8NX1Yteh-zO7_5n1c-vX64vvtdXP75dXny6qg2XtNSddqQRTMLuuhfcUEl6zgjXncSu7XsjjODSWm2F7SVztGFiY2hnpKSspR07qy5Xro16p-bkR532KmqvjgcxbZVOYDs4JV3bMd1iLMyGN20rrDFO0I1gmlK70cD6uLLmpRudNbAv7PgE-rQz-UFt440ihAjcNhQI7-4IKf5aXC5q9PnwPHpyccmK4VaSDWWcgfTtP9JdXNIEb3VQiZZhQQ5AuqpMijkn19-7IVgdcqbWnCnImTrmTDUw9ObxHvcjf1MFArYKMrSmrUsPd_8H-wceGOP5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3068630812</pqid></control><display><type>article</type><title>Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation</title><source>Publicly Available Content Database</source><source>Full-Text Journals in Chemistry (Open access)</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Kim, Dong Hyun ; Shin, Dong-Yeop ; Koh, Youngil ; Kim, Inho ; Yoon, Sung-Soo ; Byun, Ja Min ; Hong, Junshik</creator><creatorcontrib>Kim, Dong Hyun ; Shin, Dong-Yeop ; Koh, Youngil ; Kim, Inho ; Yoon, Sung-Soo ; Byun, Ja Min ; Hong, Junshik</creatorcontrib><description>This study aimed to assess the efficacy of dual T-cell suppression using individually tailored doses of antithymocyte globulin (ATG) and attenuated dose of post-transplant cyclophosphamide (PTCy) in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). We conducted a retrospective analysis of 78 adults with acute leukemia or myelodysplastic syndrome who underwent haplo-HSCT using intravenous busulfan and fludarabine conditioning. Thirty-two patients received attenuated ATG/PTCy, while 46 patients received ATG (7.5 mg/kg) as GVHD prophylaxis. The 100-day cumulative incidence of grade III-IV (9.7% vs. 32.4%,
P
= 0.018) acute GVHD, as well as 2-year moderate-severe chronic GVHD (13.9% vs. 43.9%,
P
= 0.018) in the ATG/PTCy group were significantly lower than those in the ATG group. The 2-year overall survival was comparable between the two groups. However, 2-year GVHD-free, relapse-free survival in the ATG/PTCy group was significantly higher compared to that in the ATG group (38.9% vs. 21.7%,
P
= 0.021). Moreover, during post-engraftment period, the ATG/PTCy group exhibited lower incidences of life-threatening bacterial (12.5% vs. 37%,
P
= 0.033) and viral infection (0% vs. 17.4%,
P
= 0.035) than the ATG group. In conclusion, the combination of individually tailored ATG and low-dose PTCy appears to be a promising strategy in haplo-HSCT.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-024-64361-5</identifier><identifier>PMID: 38880835</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/1904 ; 692/4028/67/1990/283 ; Adolescent ; Adult ; Anti-thymocyte globulin ; Antilymphocyte serum ; Antilymphocyte Serum - administration & dosage ; Antilymphocyte Serum - therapeutic use ; Busulfan ; Cyclophosphamide ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - therapeutic use ; Female ; Fludarabine ; Globulins ; Graft vs Host Disease - etiology ; Graft vs Host Disease - prevention & control ; Graft-versus-host disease ; Graft-versus-host reaction ; Haploidentical hematopoietic stem cell transplantation ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic stem cells ; Humanities and Social Sciences ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - therapeutic use ; Leukemia ; Lymphocyte Depletion - methods ; Lymphocytes T ; Male ; Middle Aged ; multidisciplinary ; Myelodysplastic syndrome ; Myelodysplastic Syndromes - therapy ; Peripheral Blood Stem Cell Transplantation - methods ; Post-transplant cyclophosphamide ; Prophylaxis ; Retrospective Studies ; Science ; Science (multidisciplinary) ; Stem cell transplantation ; Stem cells ; T-Lymphocytes - immunology ; Thymocytes ; Transplantation Conditioning - methods ; Transplantation, Haploidentical - methods ; Young Adult</subject><ispartof>Scientific reports, 2024-06, Vol.14 (1), p.13885-9, Article 13885</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c492t-bae15839005af84c291f4314ab90e6ffc8c849ddad8df93e25387c2bc992362b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3068630812/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3068630812?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38880835$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Dong Hyun</creatorcontrib><creatorcontrib>Shin, Dong-Yeop</creatorcontrib><creatorcontrib>Koh, Youngil</creatorcontrib><creatorcontrib>Kim, Inho</creatorcontrib><creatorcontrib>Yoon, Sung-Soo</creatorcontrib><creatorcontrib>Byun, Ja Min</creatorcontrib><creatorcontrib>Hong, Junshik</creatorcontrib><title>Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>This study aimed to assess the efficacy of dual T-cell suppression using individually tailored doses of antithymocyte globulin (ATG) and attenuated dose of post-transplant cyclophosphamide (PTCy) in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). We conducted a retrospective analysis of 78 adults with acute leukemia or myelodysplastic syndrome who underwent haplo-HSCT using intravenous busulfan and fludarabine conditioning. Thirty-two patients received attenuated ATG/PTCy, while 46 patients received ATG (7.5 mg/kg) as GVHD prophylaxis. The 100-day cumulative incidence of grade III-IV (9.7% vs. 32.4%,
P
= 0.018) acute GVHD, as well as 2-year moderate-severe chronic GVHD (13.9% vs. 43.9%,
P
= 0.018) in the ATG/PTCy group were significantly lower than those in the ATG group. The 2-year overall survival was comparable between the two groups. However, 2-year GVHD-free, relapse-free survival in the ATG/PTCy group was significantly higher compared to that in the ATG group (38.9% vs. 21.7%,
P
= 0.021). Moreover, during post-engraftment period, the ATG/PTCy group exhibited lower incidences of life-threatening bacterial (12.5% vs. 37%,
P
= 0.033) and viral infection (0% vs. 17.4%,
P
= 0.035) than the ATG group. In conclusion, the combination of individually tailored ATG and low-dose PTCy appears to be a promising strategy in haplo-HSCT.</description><subject>631/250/1904</subject><subject>692/4028/67/1990/283</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-thymocyte globulin</subject><subject>Antilymphocyte serum</subject><subject>Antilymphocyte Serum - administration & dosage</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Busulfan</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Fludarabine</subject><subject>Globulins</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - prevention & control</subject><subject>Graft-versus-host disease</subject><subject>Graft-versus-host reaction</subject><subject>Haploidentical hematopoietic stem cell transplantation</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic stem cells</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Leukemia</subject><subject>Lymphocyte Depletion - methods</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic Syndromes - therapy</subject><subject>Peripheral Blood Stem Cell Transplantation - methods</subject><subject>Post-transplant cyclophosphamide</subject><subject>Prophylaxis</subject><subject>Retrospective Studies</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>T-Lymphocytes - immunology</subject><subject>Thymocytes</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Haploidentical - methods</subject><subject>Young Adult</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kstu1DAUhiMEolXpC7BAltiwCfiWjL1CqNwqVWJT1pZjOxOPnDjYTqt5Ml6PM5PSCwuyyZHPfz7_x_qr6jXB7wlm4kPmpJGixpTXLWctqZtn1SnFvKkpo_T5o_qkOs95h-FrqOREvqxOmBACC9acVr8_Lzqg69q4EJB1c3DFxwnd-jIgP1l_4y0Iwh4V7UNMziI9FV-XYT9Gsy8ObUPsluAnOIdeKW5adAGZjdmh2KM55lKXpKc8BxhFZm9CnIeY50GP3jq4BQ16DhFqIBtwM7vk58ElKHNxIzp6e0Dog8NX1Yteh-zO7_5n1c-vX64vvtdXP75dXny6qg2XtNSddqQRTMLuuhfcUEl6zgjXncSu7XsjjODSWm2F7SVztGFiY2hnpKSspR07qy5Xro16p-bkR532KmqvjgcxbZVOYDs4JV3bMd1iLMyGN20rrDFO0I1gmlK70cD6uLLmpRudNbAv7PgE-rQz-UFt440ihAjcNhQI7-4IKf5aXC5q9PnwPHpyccmK4VaSDWWcgfTtP9JdXNIEb3VQiZZhQQ5AuqpMijkn19-7IVgdcqbWnCnImTrmTDUw9ObxHvcjf1MFArYKMrSmrUsPd_8H-wceGOP5</recordid><startdate>20240616</startdate><enddate>20240616</enddate><creator>Kim, Dong Hyun</creator><creator>Shin, Dong-Yeop</creator><creator>Koh, Youngil</creator><creator>Kim, Inho</creator><creator>Yoon, Sung-Soo</creator><creator>Byun, Ja Min</creator><creator>Hong, Junshik</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240616</creationdate><title>Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation</title><author>Kim, Dong Hyun ; Shin, Dong-Yeop ; Koh, Youngil ; Kim, Inho ; Yoon, Sung-Soo ; Byun, Ja Min ; Hong, Junshik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-bae15839005af84c291f4314ab90e6ffc8c849ddad8df93e25387c2bc992362b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/250/1904</topic><topic>692/4028/67/1990/283</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-thymocyte globulin</topic><topic>Antilymphocyte serum</topic><topic>Antilymphocyte Serum - administration & dosage</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Busulfan</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Fludarabine</topic><topic>Globulins</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - prevention & control</topic><topic>Graft-versus-host disease</topic><topic>Graft-versus-host reaction</topic><topic>Haploidentical hematopoietic stem cell transplantation</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic stem cells</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Leukemia</topic><topic>Lymphocyte Depletion - methods</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic Syndromes - therapy</topic><topic>Peripheral Blood Stem Cell Transplantation - methods</topic><topic>Post-transplant cyclophosphamide</topic><topic>Prophylaxis</topic><topic>Retrospective Studies</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>T-Lymphocytes - immunology</topic><topic>Thymocytes</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Haploidentical - methods</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Dong Hyun</creatorcontrib><creatorcontrib>Shin, Dong-Yeop</creatorcontrib><creatorcontrib>Koh, Youngil</creatorcontrib><creatorcontrib>Kim, Inho</creatorcontrib><creatorcontrib>Yoon, Sung-Soo</creatorcontrib><creatorcontrib>Byun, Ja Min</creatorcontrib><creatorcontrib>Hong, Junshik</creatorcontrib><collection>Springer_OA刊</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database (ProQuest)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Dong Hyun</au><au>Shin, Dong-Yeop</au><au>Koh, Youngil</au><au>Kim, Inho</au><au>Yoon, Sung-Soo</au><au>Byun, Ja Min</au><au>Hong, Junshik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2024-06-16</date><risdate>2024</risdate><volume>14</volume><issue>1</issue><spage>13885</spage><epage>9</epage><pages>13885-9</pages><artnum>13885</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>This study aimed to assess the efficacy of dual T-cell suppression using individually tailored doses of antithymocyte globulin (ATG) and attenuated dose of post-transplant cyclophosphamide (PTCy) in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). We conducted a retrospective analysis of 78 adults with acute leukemia or myelodysplastic syndrome who underwent haplo-HSCT using intravenous busulfan and fludarabine conditioning. Thirty-two patients received attenuated ATG/PTCy, while 46 patients received ATG (7.5 mg/kg) as GVHD prophylaxis. The 100-day cumulative incidence of grade III-IV (9.7% vs. 32.4%,
P
= 0.018) acute GVHD, as well as 2-year moderate-severe chronic GVHD (13.9% vs. 43.9%,
P
= 0.018) in the ATG/PTCy group were significantly lower than those in the ATG group. The 2-year overall survival was comparable between the two groups. However, 2-year GVHD-free, relapse-free survival in the ATG/PTCy group was significantly higher compared to that in the ATG group (38.9% vs. 21.7%,
P
= 0.021). Moreover, during post-engraftment period, the ATG/PTCy group exhibited lower incidences of life-threatening bacterial (12.5% vs. 37%,
P
= 0.033) and viral infection (0% vs. 17.4%,
P
= 0.035) than the ATG group. In conclusion, the combination of individually tailored ATG and low-dose PTCy appears to be a promising strategy in haplo-HSCT.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38880835</pmid><doi>10.1038/s41598-024-64361-5</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2024-06, Vol.14 (1), p.13885-9, Article 13885 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_9e6b3a6008c745668dcce82783a22d7a |
| source | Publicly Available Content Database; Full-Text Journals in Chemistry (Open access); PubMed Central; Springer Nature - nature.com Journals - Fully Open Access |
| subjects | 631/250/1904 692/4028/67/1990/283 Adolescent Adult Anti-thymocyte globulin Antilymphocyte serum Antilymphocyte Serum - administration & dosage Antilymphocyte Serum - therapeutic use Busulfan Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use Female Fludarabine Globulins Graft vs Host Disease - etiology Graft vs Host Disease - prevention & control Graft-versus-host disease Graft-versus-host reaction Haploidentical hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Humanities and Social Sciences Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Leukemia Lymphocyte Depletion - methods Lymphocytes T Male Middle Aged multidisciplinary Myelodysplastic syndrome Myelodysplastic Syndromes - therapy Peripheral Blood Stem Cell Transplantation - methods Post-transplant cyclophosphamide Prophylaxis Retrospective Studies Science Science (multidisciplinary) Stem cell transplantation Stem cells T-Lymphocytes - immunology Thymocytes Transplantation Conditioning - methods Transplantation, Haploidentical - methods Young Adult |
| title | Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A58%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual%20T-cell%20depletion%20with%20individually%20tailored%20anti-thymocyte%20globulin%20and%20attenuated%20dose%20of%20post-transplant%20cyclophosphamide%20in%20haploidentical%20peripheral%20stem%20cell%20transplantation&rft.jtitle=Scientific%20reports&rft.au=Kim,%20Dong%20Hyun&rft.date=2024-06-16&rft.volume=14&rft.issue=1&rft.spage=13885&rft.epage=9&rft.pages=13885-9&rft.artnum=13885&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-024-64361-5&rft_dat=%3Cproquest_doaj_%3E3068630812%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-bae15839005af84c291f4314ab90e6ffc8c849ddad8df93e25387c2bc992362b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3068630812&rft_id=info:pmid/38880835&rfr_iscdi=true |